CADTH | Evidence Driven
CADTH | Evidence Driven

bevacizumab and lomustine

Details

Files
Generic Name:
bevacizumab and lomustine
Project Status:
Complete
Therapeutic Area:
Recurrent glioblastoma multiform
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Sub Line:
Oncology Single Drug Reviews (Non-Sponsored)
Project Number:
PX0318-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
For the treatment of adult patients with glioblastoma.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input open06-Mar-23
Call for patient/clinician input closed02-May-23
Clarification:

- No patient input submission received

Call for industry input open06-Mar-23
Call for industry input closed02-May-23
Review initiated06-Mar-23
Expert committee meeting (initial)17-Oct-23
Draft recommendation posted for stakeholder feedback09-Nov-23
End of feedback period24-Nov-23

Files

Recommendation and Reasons View PDF
Responses to Questions From the Drug Programs View PDF
Clinical and Pharmacoeconomic Combined Report View PDF
Stakeholder Input - Clinicians View PDF
Stakeholder Input - Industry View PDF
Stakeholder Feedback on Draft Recommendation View PDF
Last Updated : December 20, 2023